The U.S. Food and Drug Administration today approved the use of Menactra in children as young as 9 months for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra already is approved for use in people ages 2 through 55 years.